Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis

European Journal of Cancer

Volumn 46, Issue 12, 2010, Pages 2275-2284

  Iodice, S ^a   Barile, M ^a   Rotmensz, N ^a   Feroce, I ^a   Bonanni, B ^a   Radice, P ^b   Bernard, L ^a   Maisonneuve, P ^a   Gandini, S ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

BRCA1; BRCA2; Breast cancer; Genetic epidemiology; Meta analysis; Oral contraceptives; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DISEASE CARRIER; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; META ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 77955714726     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.04.018     Document Type: Article

References (48)

1. A. Antoniou, P.D. Pharoah, and S. Narod Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 2003 1117 1130
2. T. Pal, J. Permuth-Wey, and J.A. Betts BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2005 2807 2816
3. J. Boyd BRCA: the breast, ovarian, and other cancer genes Gynecol Oncol 80 2001 337 340
4. D. Ford, D.F. Easton, D.T. Bishop, S.A. Narod, and D.E. Goldgar Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium Lancet 343 1994 692 695
5. S. Narod, D. Ford, and P. Devilee Genetic heterogeneity of breast-ovarian cancer revisited. Breast cancer linkage consortium Am J Hum Genet 57 1995 957 958
6. D.F. Easton, D. Ford, and D.T. Bishop Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium Am J Hum Genet 56 1995 265 271
7. D.F. Easton, L. Steele, and P. Fields Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13 Am J Hum Genet 61 1997 120 128
8. R. Moslehi, W. Chu, and B. Karlan BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer Am J Hum Genet 66 2000 1259 1272
9. J.P. Struewing, P. Hartge, and S. Wacholder The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1997 1401 1408
10. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer Incidence in Five Continents. Lyon; 2005.
11. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
12. D.P. Atchley, C.T. Albarracin, and A. Lopez Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer J Clin Oncol 26 2008 4282 4288
13. J.M. Dolle, J.R. Daling, and E. White Risk factors for triple-negative breast cancer in women under the age of 45 years Cancer Epidemiol Biomarkers Prev 18 4 2009 Apr 1157 1166
14. T.J. Key, P.K. Verkasalo, and E. Banks Epidemiology of breast cancer Lancet Oncol 2 2001 133 140
15. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al., editors. SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
16. J.E. Quinn, J.E. Carser, C.R. James, R.D. Kennedy, and D.P. Harkin BRCA1 and implications for response to chemotherapy in ovarian cancer Gynecol Oncol 113 2009 134 142
17. T. Riman, I. Persson, and S. Nilsson Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence Clin Endocrinol (Oxf) 49 1998 695 707
18. V. McGuire, A. Felberg, and M. Mills Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations Am J Epidemiol 160 2004 613 618
19. A.S. Whittemore, R. Harris, J. Itnyre Collaborative Ovarian Cancer Group Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women Am J Epidemiol 136 1992 1184 1203
20. M.C. King, J.H. Marks, and J.B. Mandell Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 2003 643 646
21. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
22. V. Beral, R. Doll, C. Hermon, R. Peto, and G. Reeves Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls Lancet 371 2008 303 314
23. R.B. Haynes, N. Wilczynski, K.A. McKibbon, C.J. Walker, and J.C. Sinclair Developing optimal search strategies for detecting clinically sound studies in MEDLINE J Am Med Inform Assoc 1 1994 447 458
24. K.G. Shojania, and L.A. Bero Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy Eff Clin Pract 4 2001 157 162
25. S.A. Narod, M.P. Dube, and J. Klijn Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers J Natl Cancer Inst 94 2002 1773 1779
26. K. Heimdal, E. Skovlund, and P. Moller Oral contraceptives and risk of familial breast cancer Cancer Detect Prev 26 2002 23 27
27. R.W. Haile, D.C. Thomas, and V. McGuire BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50 Cancer Epidemiol Biomarkers Prev 15 2006 1863 1870
28. J. Gronwald, T. Byrski, and T. Huzarski Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland Breast Cancer Res Treat 95 2006 105 109
29. R.M. Brohet, D.E. Goldgar, and D.F. Easton Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group J Clin Oncol 25 2007 3831 3836
30. I.B. Runnebaum, S. Wang-Gohrke, and D. Vesprini Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives Pharmacogenetics 11 2001 635 638
31. A.S. Whittemore, R.R. Balise, and P.D. Pharoah Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations Br J Cancer 91 2004 1911 1915
32. J.R. McLaughlin, H.A. Risch, and J. Lubinski Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study Lancet Oncol 8 2007 26 34
33. A.C. Antoniou, M. Rookus, and N. Andrieu Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the international BRCA1/2 carrier cohort study Cancer Epidemiol Biomarkers Prev 18 2009 601 610
34. G. Ursin, B.E. Henderson, and R.W. Haile Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57 1997 3678 3681
35. H. Jernstrom, N. Loman, O.T. Johannsson, A. Borg, and H. Olsson Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing Eur J Cancer 41 2005 2312 2320
36. R.B. Sade, A. Chetrit, and A. Figer Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers Eur J Cancer 42 2006 650 655
37. E. Lee, H. Ma, and R. McKean-Cowdin Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study Cancer Epidemiol Biomarkers Prev 17 2008 3170 3178
38. B. Modan, P. Hartge, and G. Hirsh-Yechezkel Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation N Engl J Med 345 2001 235 240
39. F. Modugno, R. Moslehi, and R.B. Ness Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States) Cancer Causes Control 14 2003 439 446
40. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
41. J.A. Sterne, P. Juni, K.F. Schulz, D.G. Altman, C. Bartlett, and M. Egger Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research Stat Med 21 2002 1513 1524
42. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
43. S.G. Thompson, and S.J. Sharp Explaining heterogeneity in meta-analysis: a comparison of methods Stat Med 18 1999 2693 2708
44. S. Greenland, and M.P. Longnecker Methods for trend estimation from summarized dose-response data, with applications to meta-analysis Am J Epidemiol 135 1992 1301 1309
45. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med JID - 8215016 2002;21:589-624.
46. J.B. Copas, and J.Q. Shi A sensitivity analysis for publication bias in systematic reviews Stat Methods Med Res 10 2001 251 265
47. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med JID - 8215016 2001;20:641-54.
48. SAS Institute Inc. SAS windows version. (8.02). Cary, NC: 1999.